Home › Acute Biphenotypic Leukemia
Acute Biphenotypic Leukemia clinical trials recruiting in the U.S.
38 studies for Acute Biphenotypic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Durham, NC8 studies
- Chicago, IL7 studies
- Memphis, TN7 studies
- Portland, OR6 studies
- Philadelphia, PA6 studies
- Aurora, CO6 studies
- Los Angeles, CA6 studies
- Charlotte, NC6 studies
- Dallas, TX6 studies
- Baldwin Park, CA6 studies
- Columbus, OH5 studies
- Tampa, FL5 studies
- Nashville, TN5 studies
- Clifton, NJ5 studies
- Boston, MA5 studies
- Fort Worth, TX5 studies
- Minneapolis, MN5 studies
- San Francisco, CA5 studies
- Greenburgh, NY5 studies
- Cincinnati, OH5 studies
- San Diego, CA5 studies
- St. Louis, MO4 studies
- Gainesville, FL4 studies
- Greenville, NC4 studies
- Orange, CA4 studies
- Indianapolis, IN4 studies
- Ann Arbor, MI4 studies
- Jacksonville, FL4 studies
- Washington, DC4 studies
- Cleveland, OH4 studies
- Milwaukee, WI4 studies
- Queens, NY4 studies
- Louisville, KY4 studies
- Omaha, NE4 studies
- Edison, NJ4 studies
- Miami, FL4 studies
By state
- Alabama3 studies
- Alaska3 studies
- Arizona4 studies
- Arkansas3 studies
- California15 studies
- Colorado8 studies
- Connecticut3 studies
- Delaware3 studies
- District of Columbia4 studies
- Florida9 studies
- Georgia9 studies
- Hawaii3 studies
- Idaho3 studies
- Illinois7 studies
- Indiana4 studies
- Iowa4 studies
- Kentucky4 studies
- Louisiana4 studies
- Maine3 studies
- Maryland4 studies
- Massachusetts5 studies
- Michigan4 studies
- Minnesota6 studies
- Mississippi3 studies
- Missouri5 studies
- Nebraska4 studies
- Nevada3 studies
- New Hampshire3 studies
- New Jersey6 studies
- New York11 studies
- North Carolina11 studies
- North Dakota3 studies
- Ohio8 studies
- Oklahoma5 studies
- Oregon6 studies
- Pennsylvania6 studies
- Rhode Island3 studies
- South Carolina3 studies
- South Dakota3 studies
- Tennessee10 studies
- Texas13 studies
- Utah3 studies
- Virginia3 studies
- Washington15 studies
- West Virginia3 studies
- Wisconsin5 studies
Recently updated studies
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 12, 2026 · NCT02115295Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04797767Personalized NK Cell Therapy in CBT
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Nov 2, 2026 · NCT02727803Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
RecruitingPhase 1/2Healthy volunteers welcome
Up to age 50 · All sexes · Updated Oct 30, 2026 · NCT05322850Prophylactic DLI-X for Leukemia Relapse After HCT
RecruitingPhase 1
Up to age 65 · All sexes · Updated Oct 29, 2026 · NCT07254793Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Oct 26, 2026 · NCT06013423Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067A Study of Revumenib and Mezigdomide in People With Leukemia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 20, 2026 · NCT07356154Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Recruiting
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07094750Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Oct 19, 2026 · NCT06575296A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecruitingPhase 1/2
30 Days · All sexes · Updated Oct 9, 2026 · NCT04065399A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Aug 10, 2026 · NCT06390319Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
RecruitingPhase 4
Ages 1 to 18 · All sexes · Updated Jul 14, 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.